Manhattan Scientifics Inc (CE) (MHTX) 시세

It's a piece of crap. Long history of never delivered promises while chairman and ceo sucked the company dry. There should be a law against it, because it happens all the time.

Looks like it's going to EM

He’s DEFINITELY shorting both companies!

Isn't it interesting how this Barry character was spot on about mhtx as it now sits in the triple zeros and its spinoff company has already fallen from 20 cents to near zero and had a huge reverse split. Nether company able to deliver on promises. Sound familiar? Didn't you and one of your minions advise investing in this company too? Don't tell me you own 100's of millions of shares of this loser as well as erhe. Next thing you'll be claiming there is great news on this company that just can't be released because the erhe gag order covers all triple zero disasters. And then what - blame it all on naked short selling? Dickran sure can pick 'em.

Spot on!!!!!!! Hidden agendas exposed!!!

You must be referring to this article:

https://www.nanalyze.com/2014/11/manhattan-scientifics-and-metallicums-nanometals/

In the comment section Barry provides interesting input:



The same Barry also interacted with another company's CEO right here, but then deleted his comment:



It seems to be a short seller shorting both companies.

Krombacher

So why would Barry Gressler care about this stock? Does Barry Gessler own shares in this company? Is Barry Gressler shorting this company?

Just curious, now that mhtx is worthless and nothing but silence from manny and marv, and imgn has reverse split and abandoned the "human instrument" that manny, marv and sproulx so fervently pitched for over a decade while wiping out those who invested at 20 cents before the r/s, what are the thoughts of rustydog and all the others who attacked, accused, and insulted me as I so truthfully pointed out what was going on here?

Shame on those who couldn't deliver on nano ti and Dr. Flynn's technology. Shame on those who blindly defended them as they fed their lifestyles while the stock prices fell and investments of others slowly disappeared.

You are quite welcome. Such a sad story watching unscrupulous, greedy people make a living by promoting companies like this one. Despicable that manny, marv and proulx used claims of "a miracle device to detect cancer" as a come on. Disgraceful to see the handful of get rich quick seekers lie and defend all the dirty dealings over so many years and relentlessly attack anyone who dared speak the truth. Now nothing but worthless shares of mhtx and reverse split decimated ibx.

In the end we all get what we deserve. Sooner or later manny, marv and proulx will get theirs.

It does seem that the Marv and Manny show is at The End...
Thanks SSC for helping make newbies aware that this company
was never anything but a legal fraud from the start....
best wishes

Nothing from you since your last brilliant due diligence on ibx new ceo who only lasted a few months before resigning. mhtx under 1/2 of a penny, ibx down to 8 cents after reverse split...hope you are ok and didn't die of embarrassment. mhtx, ibx, ntek - one hell of a trifecta lmao.

Anyone still following Imagion? New ceo left after only a few months on board; now the cfo is bailing. Rats jumping off proulx's sinking ship. Lost $13 million last year and less than $250,000 in cash left. Shares already down to 8 cents after reverse split. This last statement from ibx's latest news release sums it all up:

Given the lack of liquidity and staff reductions the consolidated entity has paused all other research and
development activities including proceeding towards an IND filing for its MagSense HER2 Breast Cancer program.

ibx "new" ceo already out the door. Looks like it didn't take him long to see how bad this mess is. And guess who is back in the driver's seat? Good old Lake Tahoe Bobbie. So discontinue the "human instrument" after a decade of wasted time and $millions of wasted money, take share price from 20 cents to near zero, reverse split the shares, hire new ceo to save the day, suffer more embarrassment as new ceo leaves after a few months, and proulx back as ceo. Meanwhile no cash to do any of the things that have been promised going as far back as the original manny and marv scam that began so many years ago.

Any more great videos or articles?

How exciting was this statement:
The Company continues to work towards its Investigational New Drug application for submission to the US FDA, which was initially planned for Q1:2024, but now likely to be delayed as Imagion works to ensure sufficient resources are in place to pursue clinical development of the MagSense imaging technology.
You don't need a magsense machine to find the coming dilution in that statement. So some good news on the technology side, same old bad story for those who bought in during the manny/marv/proulx era and recently suffered the 1:40 reverse split

https://twitter.com/mhtxscientifics/status/1732457183151788245

Yes sinking fast! Maybe will get trips?

This is going to 000s

How low can you go? How does $.0034 sound?

https://www.researchgate.net/publication/373758125_Limited_input_metal_balance_optimization_LIMBO_how_low_can_you_go

Reality check to rustydog - how about an update on that metals deal? You know, the latest scheme that put hundreds of thousands of dollars into the hands of manny and marv. Where did all that cash go? The only things shareholders know is it must have paid for a lot of trips to the lobster buffet.

You were so high on the metals deal, and now not a peep. Must be quite embarrassing to support manny and marv on one scheme after another and end up with sub-penny garbage.

Once ibx comes out with their version (if that ever happens) current shares will be diluted to worthlessness. mhtx shareholders will gain nothing from all the manny and marv years of promises, hype and lobster dinners.

By the way rustydog, how is that metals deal coming along? lmao.

Once IBX comes out with their version there will be no misdiagnosed views...

"Despite Prenuvo's focus on preventive health, many radiologists say full-body MRI scanning can do more harm than good. False positives and detection of benign abnormalities could send patients down a path of unnecessary follow-up tests and interventions." Aug 18, 2023

Interesting MRI cancer diagnostic company that actually has something that works technically and commercially. If only manny, marv, proulx had spent the last 10 years as successfully as Prenuvo did. Interesting read:

https://www.cnbc.com/2023/11/10/prenuvo-offers-2500-full-body-mri-scans-that-can-detect-cancer-early.html

Maybe new ibx ceo should be trying to partner with them or, better yet sell the whole thing and let someone who seems to know what they are doing take over.

Healthy presentation. Hmmmm. Have you seen his presentation of the upcoming 1:40 reverse split? All long time shareholders say bye bye to your investment. Ditto for scammers manny and marv and sucker mhtx shareholders. Can't wait to see how anyone tries to put lipstick on this one.

A healthy new presentation by new IBX CEO here...

Ok nvnt has new name and looks to 4xthis week. 10cents

Either a nice bottom buy or this is another scam POS ticker everyone is underwater on

Some interesting news:
Imagion Biosystems partnering with Prestige Biopharma to develop pancreatic cancer diagnosis platform

Well I hope the weak hands keep selling down here cheap while my team loads up the fleet with these shares. Had this stock on My radar for ages, and I finally started buying Monday.

This is so over sold it is nuts. Just needs volume and eyes. A problem I can solve with the historical news. The FED beat to a pulp Market has brought us so many bargains...

https://imagionbiosystems.com/news/imagion-expands-collaboration-with-siemens-healthineers-to-united-states/

I enjoyed reading this release https://investorhub.imagionbiosystems.com/announcements/4372071

A little too late for me as I sold my position, with a new CEO, this may be worth looking at in the future.. as usual Bob creates press release that can bore folks to sleep.. so here is a simple explanation.

Imagion Biosystems, a company dedicated to earlier cancer detection, said that they've achieved their goals for their first clinical study, the MagSense® HER2 breast cancer Phase 1 study, and are preparing to close the study by July 31, 2023.

What does this mean?

Well, they've developed this cool, new technology that can help change how we use MRI to spot cancer. It's like a special contrast agent that makes it easier to see cancer on an MRI image. Some independent experts in radiology checked out their work and agree that it's really promising!

So what's next?

With the success of this study, Imagion is now set to prepare a submission for a larger, multi-site Phase 2 trial in the U.S., which they hope to start by the end of 2023 or early 2024. But before they do that, they'll be making more of their special MagSense® HER2 imaging agent and completing some additional studies following the FDA's guidance.

They also plan to recruit a few more patients to test a new method of imaging after the cancerous nodes have been removed from the body. This might help them to correlate MRI findings with pathology in the upcoming Phase 2 study.

All this will take time and Lot$$$ of money and probably further dilution.

Good luck to all those still in the stock.

lol, my bad. I forgot how far this stock has fallen. Triple zeros on the way?

MHTX has been sub-penny for months. I'll take odds on MHTX.

Which goes sub-penny first, mhtx or ibx? Manny, marv, proulx, lock them up.

Here's an investor update: mhtx .0035, ibx .01

Anyone spoken with manny or marv lately? Lock them up. Proulx bailing after wasting so many years and $millions - but ain't life great at Lake Tahoe?

No one mentioning proulx baling out after taking ibx share price from 20 cents to a penny, running the Phase 1 drug trial that never ends, and diluting shareholders into oblivion. Too bad he wasn't shown the door years ago.

Wtf someone dumping huge at open

You trust the Marv? I hot a vaccine for you

Any update on the metals deal? manny and marv sucked every cent out of mhtx investors and burned thru all the $millions that came in over the years. When was the last time either one communicated with shareholders? Lock them up.

Seems odd for anyone to claim a stock is being shorted when it is under a penny. There are no reports of a large amount of mhtx short positions. The time to short mhtx would have been when it traded near 17 cents, not after it has lost almost all of its value.

What is the price of this other stock you claim "the big short seller" is shorting? Any proof regarding these large short positions?

Guys,

The big short seller shorting this issue is about to get obliterated financially in another stock he is shorting.

Take advantage of that guys.

Krombacher

They haven’t even diluted in the last year +

There is nothing left to see. Even manny and marv don't say anything about the company anymore. Out of cash, out of scam deals, out of gullible buyers. Lock them up, they've enjoyed life financed by trusting investors long enough.

Got pretty ugly here… may lose OTCQB if they don’t get back over .01 soon

Proulx strikes out again. Wanted to raise $2.5 million from existing shareholders at $.017 but got less than $500,000. Looks like his new direction (the one without a magsense instrument) isn't being received too well. So now what? Like I predicted, $millions more will most likely have to be raised at less than a penny USD. What a shameful display of incompetence while living it up at Lake Tahoe.

Point is, even a paid promoter thinks it would be great if ibx reached 3 or 4 cents again. Proulx's new direction wiped out any chance of ever seeing 10 or 20 cents again.

I always hated and will always hate paid reports. So unbiased.lol

"Readers should be aware that Pitt Street Research Pty Ltd has been engaged and paid by the company covered in this report for ongoing research coverage."

"We value Imagion at $83.1m in our base case and $126.7m
in our optimistic case using a DCF approach. This equates to
3.6c per share and 5.5c per share respectively taking into
account anticipated dilution in the next few years."

Investors update

Newsletter Highlights:

Clinical data and expert review triggers commercial partner outreach efforts
MRI utility drives new IP and AI/ML efforts
Upcoming events and a recap on key media coverage
A Message From the CEO
As we noted in our 2022 Annual Report, last year was a momentous year having reported results from the first cohort of subjects in the MagSense® HER2 Phase 1 study at a global breast cancer meeting and presenting our prostate cancer imaging agent at an imaging conference.


That momentum has continued in the first quarter of this year with the independent review we reported at the beginning of February and the recent news of our communications with the FDA related to our plans to file an IND and proceed with a multi-site study in the U.S. for the MagSense® HER2 imaging agent.


In this newsletter, we are pleased to share some of the additional activities we are undertaking to keep the momentum going.


We look forward to keeping all our stakeholders apprised of the work we are doing to change the way we look at cancer with our MagSense® molecular imaging technology.

Bob Signature 600px (2)
Strategic Partnering Data Room
Our MagSense® imaging agents could be the first-of-its-kind molecular imaging solution for MRI. By changing current practice in medical imaging to include the sensitive and selective detection of cancer cells without using radiation, Imagion’s technology could significantly improve cancer diagnosis and patient care.


Now that our MagSense® imaging agent for HER2 breast cancer detection is progressing towards Phase 2 and our technology is showing positive preclinical results in other areas of high unmet need, including prostate cancer and ovarian cancer, we have a substantial value proposition for the medical imaging sector and are now well-placed to initiate discussions around strategic options with potential commercial partners. Our current pipeline represents a projected global market opportunity of ~ $5Billion* for Imagion and our partner(s).

To facilitate the process, we have established a secure data room where we can share confidential information related to the MagSense® HER2 program as well as our growing pipeline of imaging agents and will begin outreach programs to potential partners in an effort to gauge market interest in our technology.


Parties interested in partnering with Imagion to commercialize our MagSense® molecular imaging technology can contact us via partnering@imagionbio.com.


* Total available market estimates based on market data of current testing and a projected MagSense® price of $1200.

MRI Utility Drives New Areas for IP and Analytics
Data from the MagSense® HER2 Phase 1 study and internal R&D programs have opened new opportunities for Imagion to file for intellectual property and are driving efforts to investigate how analytical methods in Artificial Intelligence (AI) and Machine Learning (ML) might be applied to improve the clinical utility of the MagSense® imaging tests.

A provisional patent application has been filed related to the image pattern(s) associated with presence of the MagSense® targeted imaging agent. This new IP would extend our proprietary position for our magnetic nanoparticles across both magnetic relaxometry and magnetic resonance imaging, providing broader protection against other imaging agents that might try to replicate targeted detection by MRI. While there is no guarantee that the patent will issue, the new IP would provide significant value to Imagion and its commercial partners, carving out a unique space in the medical imaging landscape.

Additionally, the Company has initiated a project with a 3rd party with expertise in image analysis methods including AI and ML, to determine if algorithmic solutions could be applied to the MRI scans resulting from a MagSense® test to improve interpretability. Data from the Phase 1 study has informed the initial investigations and the Company is now looking into how algorithmic solutions may help drive improvements in image acquisition in the Phase 2 study. If algorithmic solutions can be applied, it would open the opportunity for the MagSense® imaging agents to be sold with an associated Software as a Medical Device (SaaMD) solution to aid radiologists in the interpretation of the MagSense® test results.


Since all MagSense® targeted imaging agents use the same underlying magnetic nanoparticle technology, the Company would look to apply the intellectual property and image analysis solutions broadly across the portfolio of MagSense® nanoparticle imaging agents.